Erichsen G G
Nord Med. 1990;105(2):64-6.
A cost-benefit analysis of the Swedish model for screening for neoplasma malignum mammae revealed scientific shortcomings in the basis for decision. It was not possible to determine whether the screening model involved a net loss or a net profit for the individual woman. Since false confidence seems to increase the mortality in breast cancer a new dimension was introduced, a sensitivity index as an expression of revealed fractions of the incidence in the participant population. This sensitivity index estimated some two thirds of the malignant neoplasms which are normally diagnosed in a two year period.
对瑞典恶性乳腺肿瘤筛查模型的成本效益分析揭示了决策依据存在科学缺陷。无法确定筛查模型对个体女性而言是净损失还是净利润。由于虚假的信心似乎会增加乳腺癌死亡率，因此引入了一个新维度，即敏感性指数，作为参与者群体中发病率显示比例的一种表达。该敏感性指数估计了通常在两年内诊断出的约三分之二的恶性肿瘤。
